Xenon Pharmaceuticals Inc (XENE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xenon Pharmaceuticals Inc (XENE) has a cash flow conversion efficiency ratio of -0.140x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-81.48 Million) by net assets ($581.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See XENE defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Xenon Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Xenon Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Xenon Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xenon Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stella-Jones Inc.
TO:SJ
|
0.022x |
|
Tegna Inc
NYSE:TGNA
|
0.034x |
|
Financière Amuse TopCo SAS
ST:ASMDEE-B
|
0.068x |
|
Navan, Inc. Class A Common Stock
NASDAQ:NAVN
|
0.029x |
|
Nien Made Enterprise Co Ltd
TW:8464
|
0.048x |
|
Shanghai Suochen Information Technology Co. Ltd. A
SHG:688507
|
N/A |
|
Aehr Test Systems
NASDAQ:AEHR
|
-0.021x |
|
Jushri Technologies Inc Class A
SHE:300762
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Xenon Pharmaceuticals Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Xenon Pharmaceuticals Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Xenon Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $581.76 Million | $-279.12 Million | -0.480x | -99.68% |
| 2024-12-31 | $754.90 Million | $-181.39 Million | -0.240x | -53.42% |
| 2023-12-31 | $927.92 Million | $-145.33 Million | -0.157x | -14.80% |
| 2022-12-31 | $721.50 Million | $-98.43 Million | -0.136x | -7.97% |
| 2021-12-31 | $550.03 Million | $-69.50 Million | -0.126x | +55.01% |
| 2020-12-31 | $171.35 Million | $-48.12 Million | -0.281x | -457.67% |
| 2019-12-31 | $91.98 Million | $-4.63 Million | -0.050x | +85.02% |
| 2018-12-31 | $103.30 Million | $-34.72 Million | -0.336x | +57.95% |
| 2017-12-31 | $35.93 Million | $-28.73 Million | -0.799x | -161.07% |
| 2016-12-31 | $63.90 Million | $-19.57 Million | -0.306x | -3.24% |
| 2015-12-31 | $61.03 Million | $-18.10 Million | -0.297x | -8215.27% |
| 2014-12-31 | $72.78 Million | $266.00K | 0.004x | +102.65% |
| 2013-12-31 | $24.12 Million | $-3.32 Million | -0.138x | -103.82% |
| 2012-12-31 | $12.62 Million | $45.57 Million | 3.610x | -- |
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizure… Read more